Scientists in Japan have discovered a genetic "silencer" within the HTLV-1 virus that helps it stay hidden in the body, ...

Reprogrammable RNA nanoparticles activate only in cancer cells to deliver targeted gene-silencing therapy while avoiding ...

Q2 2025 Earnings Call Transcript August 1, 2025 Ocugen, Inc. beats earnings expectations. Reported EPS is $-0.05, ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

Starting in the mid-2010s, the University of Oxford pediatrician and immunologist began working with scientists in the South African province of KwaZulu-Natal, with the aim of tracking several hundred ...

If successful, the access model for sickle cell disease gene therapies could serve as a blueprint for other such treatments ...

These 10 stocks could mint the next wave of millionaires › Ocugen (NASDAQ:OCGN), a biotechnology company developing gene therapies and regenerative medicine solutions for eye diseases, released its ...

Ixo-vec reduced anti-VEGF injection frequency and was well tolerated in patients with wet AMD. A phase 3 pivotal trial ...

Daniel Cressy will be the first patient in Louisiana to complete the gene therapy treatment for sickle cell disease.